🤝 Blair Compass Companion Guide

Autoimmune Companion Guide

For the patients who don't fit a single box, and the conversations that don't have a quick answer. MCTD, overlap syndromes, undifferentiated CTD, and ready-to-paraphrase patient scripts. Pairs with the Autoimmune CDSM.

Blair Compass PCP support tool. Designed to support clinical reasoning and patient communication, not replace clinical judgment or specialist evaluation. MCTD and overlap criteria sets are orientation aids, not validated probability scores.
🩸 MCTD orientation🌈 Overlap syndromes⏳ UCTD framing💬 Patient scripts🖨️ Printable huddle sheet👥 Patient education page (EN/ES) ↗
Mixed connective tissue disease

🩸 MCTD - recognize it in primary care

One-line definition. MCTD is a distinct CTD defined by overlap features of SLE, systemic sclerosis, and polymyositis/dermatomyositis in the setting of high-titer anti-U1-RNP. It is not "early lupus" and it is not the same as undifferentiated CTD.

The PCP-level recognition triad

Raynaud's phenomenon + puffy / swollen hands + high-titer anti-U1-RNP. If two of these are present and you sent the antibody, anti-U1-RNP positivity should make you think MCTD before SLE.

Other features to ask about / examine

  • Arthritis or arthralgias (often non-erosive but can be deforming)
  • Myositis-spectrum findings - proximal weakness, dysphagia, elevated CK (use the DM/IIM calculator when myositis is dominant)
  • Sclerodactyly, telangiectasias, calcinosis
  • Esophageal dysmotility - reflux, food sticking, slow emptying
  • Interstitial lung disease - dry cough, exertional dyspnea, crackles
  • Pulmonary hypertension risk - the leading cause of MCTD mortality, screen with low threshold
  • Trigeminal neuralgia (small but classic association)

Antibody pattern that should redirect you toward MCTD

  • High-titer speckled ANA (often ≥1:1280)
  • Anti-U1-RNP positive - the defining antibody
  • Anti-dsDNA and anti-Smith typically negative - their absence helps distinguish from SLE
  • Anti-Sm positivity argues against MCTD and toward SLE
Pitfall. A high-titer speckled ANA + Raynaud's + puffy hands gets called "ANA-positive, probably early lupus" all the time. If anti-U1-RNP wasn't sent, you may be missing MCTD.
Criteria orientation

🧭 MCTD criteria checker

No single MCTD criteria set is universally accepted. This non-scoring checklist supports recognition of a compatible overlap phenotype and referral. It does not establish or exclude a diagnosis.
Select features to see how the picture aligns with each criteria set.
About the three criteria sets
Alarcón-Segovia and Villarreal. Requires anti-U1-RNP plus at least three clinical criteria, including synovitis or myositis.

Sharp. Uses a more complex major and minor feature rule with anti-U1-RNP titer requirements. This page does not reproduce or score it.

Kasukawa. Requires a common feature, anti-U1-RNP, and findings from at least two of the SLE-like, systemic-sclerosis-like, and polymyositis-like groups. This page does not score it.
When to act

🚦 Workup & referral

Labs to add when MCTD is on the differential

  • Anti-U1-RNP with titer (the diagnostic antibody)
  • Extractable nuclear antigens (ENA) panel - captures U1-RNP + Sm, SSA/Ro, SSB/La, Scl-70
  • CK, aldolase if any myositis features
  • Complements (C3, C4) - typically normal in MCTD (unlike SLE)
  • Anti-dsDNA, anti-Smith - help distinguish from SLE
  • Baseline PFTs with DLCO + HRCT chest if pulmonary symptoms or fibrotic crackles
  • Echocardiogram if any dyspnea, hypoxia, or PH suspicion

Referral threshold

Routine rheumatology for any high-titer ANA + Raynaud's + puffy hands picture once anti-U1-RNP is sent (do not wait for it to return).
Urgent rheumatology + pulmonology if dyspnea, hypoxia, fibrotic findings on imaging, or PH suspicion. PH is the leading cause of MCTD mortality and is treatable when caught early.
ED / urgent admission for severe dysphagia with aspiration risk, acute respiratory decompensation, severe digital ischemia, or hemoptysis.
Overlap syndromes

🌈 When the picture is more than one disease

Definition. Overlap syndrome = a patient simultaneously meets (or strongly resembles) classification criteria for two or more distinct CTDs. Different from MCTD, which is its own entity defined by anti-U1-RNP.

🦋🖐️ Rhupus (SLE + RA)

  • Erosive symmetric small-joint arthritis with RF and/or anti-CCP positivity, alongside SLE-defining features
  • Anti-CCP is the key clue - true SLE usually has non-erosive arthritis and CCP-negative
  • Joints can deform like RA; need DMARD strategy in addition to SLE management

🌡️ Scleroderma overlap

  • Systemic sclerosis features (skin thickening, sclerodactyly, telangiectasias, calcinosis, severe reflux, renal crisis, ILD) plus another CTD
  • SSc + myositis is common - proximal weakness with skin thickening and Raynaud's
  • Antibodies that point here: Scl-70, anti-centromere, anti-RNA polymerase III, PM-Scl, Ku

🫁 Antisynthetase syndrome don't miss

Often missed because it doesn't look like classic DM. Think antisynthetase syndrome when you see myositis + ILD + arthritis + Raynaud's + mechanic's hands + fever in any combination, especially when ILD is the leading complaint.

Recognition cues

  • Mechanic's hands - hyperkeratotic, fissured, "dirty-looking" lateral fingers/palms
  • ILD that precedes or dominates the myositis
  • Inflammatory arthritis (often hand small joints, sometimes deforming)
  • Raynaud's phenomenon
  • Fever without infection

Antibodies

  • Anti-Jo-1 (most common; already in the DM/IIM calculator)
  • Anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS, anti-Zo, anti-Ha
  • Often part of a myositis-specific / myositis-associated antibody panel
Cross-link. Anti-Jo-1 positivity scores in the 2017 EULAR/ACR IIM calculator - see the Autoimmune CDSM Calculators tab.

🧭 When you suspect overlap but can't name it yet

  • Document each organ system and each positive antibody discretely - don't collapse to a single diagnosis prematurely
  • Refer to rheumatology; if ILD features, add pulmonology in parallel
  • Set expectations with the patient - see the Patient scripts tab for the "this may take time" conversation
  • Many patients sit in UCTD for months to years before the picture crystallizes - that's a legitimate clinical state, not a diagnostic failure
Undifferentiated CTD

⏳ UCTD - "we don't know yet" is a real diagnosis

Working definition. UCTD describes clinical and serologic features of systemic autoimmune disease that do not fulfill criteria for a defined connective tissue disease. No universally accepted diagnostic criteria or minimum duration exists. One proposed preliminary classification framework uses ANA positivity on two occasions and at least 3 years of disease.

Why UCTD matters to PCPs

  • A meaningful fraction of CTD patients live in UCTD for months to years before the picture clarifies
  • Across six cohorts, about 28% evolved to a defined connective tissue disease, usually within 5 to 6 years. Individual course is variable.
  • It is not a "we missed something" diagnosis - naming it explicitly helps the patient understand their own disease state
  • Documenting UCTD prevents the patient from being labeled "ANA-positive, no diagnosis" forever, which often leads to repeated workups and lost-to-follow-up

Monitoring approach

  • Symptom diary or structured intake at each visit - new organ system involvement is the trigger to re-evaluate
  • Periodic labs: CBC, CMP, UA with micro, ESR/CRP, complements; expand antibodies only when new clinical features appear
  • Low threshold to repeat or expand serologies if a new organ system is involved (renal, neuro, pulmonary, severe cytopenia)
  • Maintain the rheum relationship - annual or semiannual rheum follow-up unless rheum hands back to PCP
expectation-setting

⏰ The timeline reality

Patients deserve to hear this directly. UCTD and overlap pictures may remain uncertain for years, and some never evolve to a defined connective tissue disease. This uncertainty is not a failure. It reflects the variable course of these diseases.
Why naming UCTD helps the patient:
  • It names their experience instead of leaving them in limbo
  • It validates that further workup makes sense without overcommitting to a diagnosis they don't have
  • It explains why their rheum appointment didn't "give them an answer" - that's how UCTD looks at the specialist level too
  • It sets up a watchful, structured follow-up rather than ad-hoc ER visits driven by uncertainty
What to say. See Script C and Script F on the Patient scripts tab.
Patient communication

💬 Ready-to-paraphrase scripts

How to use. Each script is 30–90 seconds of plain language. Paraphrase rather than read. The bolded phrases are the parts patients remember.
Script A
When: ordering the initial autoimmune workup.
"Based on what you're telling me, I want to check whether something in your immune system might be involved. That means a few blood tests and urine tests, not one single answer. Some of these tests can come back positive in healthy people, so we look at the whole picture together. I'll go through what each result means with you when they come in."
Script B
When: ANA came back positive. (Most common cause of patient panic.)
"Your ANA test is positive. That does not mean you have lupus. A positive ANA is just a starting point - it tells us your immune system is making antibodies that can be present in autoimmune disease, but also in many people who never develop one. The next step is looking at your symptoms together with more specific tests to figure out whether anything specific is going on. We do this carefully, one step at a time."
Script C
When: workup is partly back, no clear diagnosis. The UCTD conversation.
"Here's where we are: your symptoms and some of your labs are pointing toward autoimmune activity, but they don't yet fit one specific disease. That's a real and well-known situation in medicine - we call it undifferentiated connective tissue disease. It doesn't mean we missed something. It means your body hasn't shown us enough yet to name a specific disease. Our plan is to watch this carefully, treat the symptoms that bother you, and look again if new things come up."
Script D
When: sending the patient to rheumatology.
"I'm sending you to a rheumatologist - a specialist in immune-system diseases. One thing I want you to know up front: it's normal if the rheumatologist doesn't give you a final diagnosis at the first visit. These conditions can take time to declare themselves. The specialist may order more tests, watch how things change over a few months, and then put it all together. That's how this is supposed to work."
Script E
When: closing the visit. Red-flag safety net.
"Most of what we're doing is patient and stepwise. But there are a few things I want you to call us about right away: shortness of breath that's new or worsening, chest pain, severe weakness, trouble swallowing or choking, a new rash with fever, severely cold or blue fingers that won't warm up, or any seizure or confusion. Those would change our plan immediately. Otherwise, we'll see each other on schedule and follow the labs."
Script F
When: the patient pushes for certainty. The 2-year framing.
"I hear you - uncertainty is genuinely hard. I want to be straight with you. Some of these autoimmune conditions, including mixed connective tissue disease, can take on average around two years before they declare themselves clearly enough to name. That's not because we're not trying. It's because the diseases themselves take time to show all their features. What we can do meanwhile is watch closely, keep you safe, and treat the symptoms that affect your life. I'm not going anywhere - we'll go through this together."
👥 Hand the patient something to take home. The bilingual patient guide Understanding Your Autoimmune Workup on public.blaircompass.com covers the same ground in plain language - ANA reframe, UCTD/MCTD timeline, what to expect from rheum, red flags, and FAQs. Free, no login required, English & Español. Print it or link it in the visit summary.
Clinician reference

🖨️ Printable huddle sheet

Best printed in portrait, letter size.

Autoimmune Companion - Workstation Huddle Reference

🩸 MCTD recognition triad

Raynaud's + puffy/swollen hands + high-titer anti-U1-RNP (ANA often ≥1:1280, speckled). Anti-dsDNA/Smith typically negative.

Don't miss: ILD and pulmonary hypertension drive mortality - low threshold for PFTs + DLCO and echo.

🌈 Overlap red flag - antisynthetase syndrome

Myositis + ILD + arthritis + Raynaud's + mechanic's hands + fever. Send myositis antibody panel (Jo-1, PL-7, PL-12, EJ, OJ). Rheum + pulm.

⏳ UCTD reminder

CTD symptoms + positive ANA + ≥1 year, doesn't meet criteria for a defined CTD. ~1/3 progress (often to SLE). Naming it helps the patient and prevents repeat workups.

💬 Top scripts (compact)

ANA positive: "A positive ANA does not mean you have lupus. It's a starting point. We look at the whole picture."

No clear diagnosis (UCTD): "We call this undifferentiated connective tissue disease. It doesn't mean we missed something - it means your body hasn't shown us enough yet."

Going to rheum: "It's normal if the rheumatologist doesn't give you a final diagnosis at the first visit. These conditions can take time to declare themselves."

Patient pushes for certainty: "Some of these - including MCTD - can take around two years to declare themselves clearly. That's how the disease behaves, not a failure of effort."

🚨 Call us / ED criteria (give the patient)

New or worsening shortness of breath · chest pain · severe weakness · trouble swallowing or choking · new rash with fever · severely cold/blue fingers that won't warm · seizure or new confusion.

Companion to the Blair Compass Autoimmune CDSM. Educational use only - does not replace clinical judgment or specialist evaluation.

sources

🔗 References & further reading

TopicSource
MCTD - state of the art on clinical practice guidelinesPMC - MCTD review
MCTD - toward early diagnosis (updated perspectives)PMC - early diagnosis review
MCTD criteria sets (Alarcón-Segovia / Sharp / Kasukawa) summaryStatPearls - MCTD chapter
Antisynthetase syndrome - diagnosis & treatmentPMC - Witt et al.
2017 EULAR/ACR Idiopathic Inflammatory Myopathy criteria (used in CDSM)PMC - Lundberg et al.
2019 EULAR/ACR SLE classification criteria (used in CDSM)PMC - Aringer et al.
UCTD - evolutionary trajectory & impact of 2019 SLE criteriaPMC - longitudinal UCTD study
ACR patient resource - connective tissue diseasesAmerican College of Rheumatology
Lupus Foundation of America - patient resourceslupus.org
Sister tool - Autoimmune CDSM (workflow, calculators, Don't-Miss DM)Open Autoimmune CDSM →
Patient-facing autoimmune education (bilingual, no login required)Understanding Your Autoimmune Workup - EN / ES →
Review note. Rheumatology review may be incorporated in future updates. MCTD/overlap diagnosis is an evolving area - none of the three MCTD criteria sets has been universally adopted. Use criteria orientation here for reasoning, not classification.
PREPARED BY RAYMOND BLAIR, MD EST. 2025 IRON PASSAGE HOLDINGS B

Authoritative sources

Educational support only. Verify patient-specific decisions against current source guidance and local policy.